

Xylamidor 20 mg/ml Injektionslösung für Tiere

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:

Xylamidor 20 mg/ml Injektionslösung für Tiere

Active substance:

Xylazine hydrochloride

Target species:

Cattle

Dog

Cat

Horse

Route of administration:

Intramuscular use

Intravenous use

Subcutaneous use

Product details

Active substance and strength:

Xylazine hydrochloride

23.32 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

•

Cattle

- Meat and offal. 1 day
- Milk. 0 hour

Intravenous use:

•

Cattle

- Meat and offal. 1 day
- Milk. 0 hour

•

Horse

- Meat and offal. 1 day
- Milk. 0 hour

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM92

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Available in:

Norway

Package description:

Clear glass vial type I with 5 x 10 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap in a cardboard box.

Clear glass vial type II with 25 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.

Clear glass vial type II with 50 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.

Clear glass vial type I with 10 ml solution for injection with a coated bromobutyl rubber stopper, type I and aluminium cap.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Vetviva Richter GmbH

Marketing authorisation date:

5/07/2023

Manufacturing sites for batch release:

Vetviva Richter GmbH

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

22-14676

Date of authorisation status change:

5/07/2023

Reference member state:

Austria

Procedure number:

AT/V/0029/001

Concerned member states:

Belgium Bulgaria Cyprus Denmark Finland France Germany Greece Ireland
Italy Latvia Netherlands Norway Poland Romania Slovakia Slovenia Spain
Sweden

Generic of:

600000072350

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 11/08/2023

Updated on: 13/03/2026

[Download](#)

Combined File of all Documents

at-puar-atv0029001-mr-xylaemidoer-en.pdf